Driving success and time-to-market in clinical drug development

The clinical drug development market is teeming with innovation, including cell and gene therapies, digital therapeutics, personalized medicine and biomarkers, and the integration of drugs and medical devices. However, despite these breakthroughs, many life sciences organizations are not able to fully capitalize on the advancements.

Innovation promises to usher in a new era of opportunity for life sciences companies. However, it will also add new levels of complexity to the development process, heightening the need to solve core challenges related to access, speed and effectiveness.

As the clinical landscape becomes both more complex and more competitive, now is the time to embrace the transformative strategies, advanced digital and data capabilities, and innovative trial designs that will enable a true next-gen clinical trial function—driving success and time-to-market across the drug development lifecycle.

 

“Because of recent significant global events, energy priorities have been redefined. In this year’s World Energy Markets Observatory, we explore our urgent need to accelerate the energy transition while managing the security of supply, sovereignty of energy production, equipment and resources, and ensuring energy affordability.”
James Forrest
Group Industry Leader for Energy Transition and Utilities at Capgemini